In this context, given the major role of LGALS9 in Treg immunosuppressive activity, we propose to evaluate our anti-LGALS9 immunotherapy protocol, specifically developed to neutralize LGALS9 and Treg-suppressive activity, in a transgenic KC mouse model of pancreatic cancer. Here, LGALS9 is linked to familial pancreatic carcinoma.